## **ETH** zürich

## Monitoring of antibody glycosylation pattern based on microarray MALDI-TOF mass spectrometry

**Journal Article** 

Author(s):

Hajduk, Joanna; Wolf, Moritz (); Steinhoff, Robert; Karst, Daniel; Souquet, Jonathan; Broly, Hervé; Morbidelli, Massimo; Zenobi, Renato ()

Publication date: 2019-08-20

Permanent link: https://doi.org/10.3929/ethz-b-000351707

Rights / license: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

Originally published in: Journal of Biotechnology 302, <u>https://doi.org/10.1016/j.jbiotec.2019.06.306</u>

| WD | VCD [10 <sup>6</sup> cells/day] | Titer [g/L] |
|----|---------------------------------|-------------|
| 1  | 38.453                          | 0.379       |
| 2  | 39.113                          | 0.471       |
| 3  | 39.947                          | 0.518       |
| 4  | 36.994                          | 0.472       |
| 5  | 39.495                          | 0.470       |
| 6  | 38.384                          | 0.439       |
| 7  | 39.634                          | 0.430       |
| 8  | 40.034                          | 0.308       |
| 9  | 39.582                          | 0.364       |
| 10 | 39.426                          | 0.351       |
| 11 | 39.704                          | 0.397       |
| 12 | 46.964                          | 0.390       |
| 13 | 49.370                          | 0.375       |
| 14 | 49.971                          | 0.411       |
| 15 | 51.371                          | 0.340       |
| 16 | 52.972                          | 0.289       |
| 17 | 49.646                          | 0.308       |
| 18 | 50.571                          | 0.299       |

**Table S1.** mAb quantification based on Protein A HPLC-UV analysis. Abbreviations: WD – working day, VCD – viable cell density.

## **Perfusion cell culture conditions:**

A stable culture at both viable cell density set points of 40 and 50x10<sup>6</sup> cells/mL was achieved over the entire 18-day run. The cell viability remained above 90%. The extracellular glucose level varied between 16.1 and 24.6 mmol/L during the first set point, and 14.4 and 19.6 mmol/L during the second cell density set point. Lactate concentrations ranged between 11.1 and 17.8 mmol/L, and between 6.9 and 10.7 mmol/L, respectively. After an initial transition period resulting from cell inoculation to the perfusion bioreactor, as well as the change of the cell density set point, Glc (20.8, and 16.2 mmol/L) and Lac (14.2, and 6.6 mmol/L) concentrations approached constant levels during each of the steady states.



**Figure S1.** MALDI-TOF MS spectra of standard FA2 glycopeptide in the concentration range from 10 to 0.01 pmol/ $\mu$ L. MAMS sample deposition (A-D) vs. conventional deposition on a stainless-steel target (E-H). The recorded m/z: 2104.93 (M+H)<sup>+</sup>; 2126.92 (M+Na)<sup>+</sup>, 2142.88 (M+K)<sup>+</sup>, 2148.89 (M+Na-H)<sup>+</sup>. The signal-to-noise ratios (s/n) are plotted for the major peaks, and was found to be 3.5 times higher for the MAMS samples. The FA2 glycopeptide amino acid sequence: KVANKT.



**Figure S2**. CGE-LIF reference analysis of FA2 (red triangular, dotted line) and FA2G1(green triangular, dotted line) N-glycan structure.



**Figure S3.** CGE-LIF reference analysis of N-glycan's minor fraction: high mannose (M5+M6+M7; open square, dotted line), A2 (black square, dotted line), FA2G2 (open circle, dotted line) and sialylated forms (SIA; black diamond, dotted line).



Figure S4. Viable cell density (VCD) as a function of time.